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Highlights 
 Diagnosis of HBoV1 has been based on detection of DNA or mRNA. 
 Rapid HBoV1 antigen detection is beneficial for diagnosing acute HBoV1 infections. 
 HBoV1 antigen detection is attractive for point-of-care use.  
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Background 
Human bocavirus 1 (HBoV1) is a common cause of respiratory tract infections (RTI) in young 
children and causes serious lower RTI in children younger than six years of age (1-5). The 
diagnosis of HBoV1 infections has traditionally been based on qualitative PCRs detecting viral 
DNA. Recent studies have however shown that the clinical value of this approach is low due to 
persistence of HBoV1 DNA in the airways, leading to frequent detection of low concentrations 
in healthy children (6-8). Clinical specificity of HBoV1 mRNA detection has been shown to be 
superior to that of HBoV1 DNA detection (6, 9, 10).  
Detection of HBoV1 antigen is another diagnostic approach. An automated HBoV1 antigen test 
based on immunometric detection has recently been developed and has shown promise in 
preliminary studies (11). Antigen detection is well suited for automation and point-of-care 
diagnostics, and may be beneficial to making an HBoV1 diagnosis by providing rapid and 
specific results.  
Objectives 
The aim of this study was to compare HBoV1 antigen detection with HBoV1 mRNA RT-PCR 
and quantitative HBoV1 DNA detection (qPCR) in nasopharyngeal swabs (NPS) from children 
with RTI.  
Study design 
NPS (N=632) were collected from children admitted for RTI to the Pediatric Emergency 
Department of Turku University Hospital from November 2015 to October 2016. All samples 
were stored in mariPOC RTI sample buffer at -20°C throughout the study period. 
The HBoV1 antigen test is part of a completely automated system for multianalyte 
identification of respiratory viruses and bacteria (influenzavirus A, influenzavirus B, 
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respiratory syncytial virus, human coronavirus OC43, human metapneumovirus, human 
bocavirus 1, parainfluenzavirus type 1, parainfluenzavirus type 2, parainfluenzavirus type 3, 
adenovirus, Streptococcus pneumonia) and has IVD-CE approval for diagnostic testing 
(mariPOC® respi test, ArcDia International Ltd, Turku, Finland). It is an immunoassay based 
on separation-free two-photon excitation fluorometry and targets the HBoV1 capsid protein 
VP3 (12). The mariPOC test reports strong positive samples in 20 minutes while low-positive 
and negative results are confirmed in 2 hours. For mariPOC, NPSs were diluted in 1.3 mL of 
mariPOC RTI sample buffer for rapid prospective on-site testing on a random-access 
immunoassay analyzer.  
The test was in routine use at the Pediatric Emergency Department of Turku University Hospital 
for rapid point-of-care diagnostics of RTI throughout the study period. According to local 
guidelines, the mariPOC antigen test is used for all children hospitalized with acute RTI. This 
Pediatric Emergency Department serves a population of 70 000 children or adolescents (<16 
years of age) and receives patients mostly by referral from primary care clinics. The majority 
of children hospitalized with RTIs are younger than 5 years of age and have lower RTIs.  
The Turku University Hospital approved the study with a waiver of informed consent by the 
Ethics Committee, as the study involved reanalysis of de-identified samples collected as part of 
routine care. 
All samples were analyzed in duplicate with HBoV1 DNA qPCR and HBoV1 mRNA reverse-
transcription (RT)-PCR, as described previously (10, 13). The cutoff for a high viral load in 
DNA qPCR was >106 copies/mL. 
Correlations between mRNA, high DNA load and antigen were measured by the phi coefficient 
of correlation. Sensitivity, specificity, and positive predictive value (PPV) for the antigen test 
were calculated by using mRNA RT-PCR and DNA qPCR as references. 
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Results 
HBoV1 DNA, a high DNA load, mRNA, or antigen were detected in 96 (15.2 %), 19 (3 %), 17 
(2.7 %), and 13 (2.1 %) of the 632 NPA samples, respectively (Table 1). Out of the 96 samples 
positive for DNA, only 19.8 % had a high DNA load, 17.7 % were positive for mRNA, and 
13.5 % for antigen. Of the samples with a high DNA load, 89.5 % were positive for mRNA and 
68.4 % for antigen, whereas none of the low DNA-load samples harbored mRNA or antigen. 
Positive HBoV1 antigen test results were available in 20 minutes for nine of the 13 samples, 
and the four remaining results were available in two hours. 
Presence of HBoV1 antigen correlated well with both mRNA and high DNA load. The phi 
coefficient for the correlation between mRNA and antigen was 0.87, whereas it was 0.94 for 
mRNA and high DNA load. 
Specificity and PPV of the HBoV1 antigen test were excellent, while the sensitivity was lower. 
With mRNA RT-PCR as reference, specificity, sensitivity, and PPV were 100 %, 76.5 %, and 
100 %, respectively. With high DNA load by qPCR as reference, the figures were 100 %, 
68.4%, and 100% (Table 2). 
Discussion 
The widely used qualitative HBoV1 DNA PCRs yield results of low clinical specificity and 
very low PPV (1, 2, 6, 7, 14). We confirmed this. With mRNA RT-PCR as a reference, the 
qualitative DNA PCR specificity and PPV were 87.2 %, and 17.7 %, respectively (Table 2).  
Serological tests based on detection of HBoV1-specific IgM and increases of IgG in paired 
serum samples are well-established reference methods in clinical studies (1, 2, 6, 14). However, 
sera were not obtained from the children included in this study. Instead, we used mRNA 
detection and high DNA load as the basis for calculating specificities, sensitivities and PPVs. 
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mRNA is a marker of actively transcribing virus during an ongoing infection, and a rapidly 
declining DNA load is the normal outcome after an acute infection. The HBoV1 mRNA test 
has performed well in studies, providing support for its use as reference (6, 7, 9, 10). 
Furthermore, a high DNA load (>104 or >106 copies/mL) in nasopharyngeal secretions has been 
shown to be a better diagnostic criterion than mere DNA detection by endpoint PCR (8, 14-16). 
The two tests together should therefore form a good basis for evaluating the antigen test. 
Detection rates of 15 % for HBoV1 DNA, 2.7 % for mRNA and 3.0 % for high DNA load (>106 
copies/mL) in children with RTI are in agreement with previous reports in the literature (7, 9, 
10, 14, 15). Taken together, the results suggest that only about a fifth of the children with 
HBoV1 DNA in the nasopharynx has an acute HBoV1 infection.  
In our study, the samples had been stored at -20°C for up to two years, therefore some 
degradation of RNA cannot be excluded. The storage temperature recommended for RNA is 
usually -70°C. The sensitivity of the HBoV1 antigen test could have been overestimated if RNA 
degradation had occurred. However, the mRNA positivity rate reflected that of the high DNA 
load, indicating that this effect was small. Furthermore, with an amplicon of 242 bp, the 
probability of degradation within the target sequence is low, explaining the limited effect of 
RNA degradation on the results. 
Among adults with RTI, HBoV1 DNA is rarely detected. Sample sizes in studies on adults have 
been too small to conclude the clinical significance of HBoV1-DNA positivity (1-2).  
We conclude that HBoV1 antigen detection is excellent for diagnosing acute HBoV1 infections 
in children. Compared with two independent reference assays, this antigen test shows 
substantially higher clinical specificity and PPV than the commonly used HBoV1 qualitative 
DNA PCRs. The sensitivity of the HBoV1 antigen test is lower than those of the PCRs, but it 
has the advantage of being a rapid test available for point-of-care use, with positive results 
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usually available in 20 minutes, resulting in a faster diagnosis than traditional methods. This 
makes the test attractive for emergency room and outpatient use. A supplementary test, 
measuring HBoV1 DNA load, mRNA or specific antibodies, will be of value for higher 
sensitivity in an inpatient setting. 
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Table 1. Results of the HBoV1 diagnostic tests in relation to detection of HBoV1 mRNA and 
HBoV1 DNA quantity (N=632). 
  
No. 
HBoV1 mRNA+ 
No. (%) 
HBoV1 mRNA – 
No. (%) 
HBoV1 antigen 
Pos 13 13 (100) 0 
Neg 619 4 (0.6) 615 (99.4) 
HBoV1 DNA quantity  
Higha 19 17 (89.5) 2 (10.5) 
Lowa/neg 613 0 613 (100) 
HBoV1 DNA presence 
Pos 96 17 (17.7) 79 (82.3) 
Neg 536 0 536 (100) 
     
 
 
 HBoV1 DNA high 
load 
HBoV1 DNA low 
load 
or negative 
  No. No. (%) No. (%) 
HBoV1 antigen 
Pos 13 13 (100) 0 
Neg 619 6 (1.0) 613 (99.0) 
HBoV1 mRNA 
Pos 17 17 (100) 0 
Neg 615 2 (0.3) 613 (99.7) 
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aHigh HBoV1 DNA load: ≥106 copies/mL NPA; low load: <106 copies/mL NPA 
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Table 2. Performances of the HBoV1 diagnostic tests, with mRNA RT-PCR or DNA qPCR as 
reference markers. 
Diagnostic marker 
vs. reference 
Specificity  
% (95 % CI) 
Sensitivity 
% ( 95 % CI) 
PPV 
% (95 % CI) 
Antigen  
vs. mRNA 
100 (99.4 – 100) 76.5 (52.7 – 90.4) 100 (77.2 – 100) 
Antigen  
vs. DNA quantitya 
100 (99.4 – 100) 68.4 (46.0 – 84.6) 100 (77.2 – 100) 
DNA quantitya  
vs. mRNA 
99.7 (98.8 – 99.9) 100 (81.6 – 100) 89.5 (68.6 – 97.1) 
mRNA  
vs. DNA quantitya  
100 (99.4 – 100) 89.5 (68.6 – 97.1) 100 (81.6 – 100) 
DNA presence  
vs. mRNA 
87.2 (84.3 – 89.6) 100 (81.6 – 100) 17.7 (11.4 – 26.5) 
aHigh HBoV1 DNA load: ≥106 copies/mL NPA. 95 % CI, Confidence Interval (Wilson Score 
Method); PPV, positive predictive value 
 
